Cerus Investor Relations Material
Latest events
Q1 2025
Cerus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cerus Corporation
Access all reports
Cerus Corporation develops and markets blood safety technologies intended to reduce the risk of transfusion-transmitted infections. Its INTERCEPT platform is used to treat blood components such as platelets and plasma. The company serves blood centers, hospitals, and transfusion services. The company is headquartered in Concord, California, and its shares are listed on the NASDAQ.
Key slides for Cerus Corporation
Corporate Presentation
Cerus Corporation
Corporate Presentation
Cerus Corporation
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
CERS
Country
🇺🇸 United States